>_ QFI Terminal
Terminal › Stocks › LNAI

Lunai Bioworks Inc. (LNAI) Stock

Healthcare · Biotechnology · US
$0.16 -30.20%
Last updated Nov 12, 2026 10:46 UTC

LNAI Key Statistics

Market Cap$2.93M
P/E (TTM)-0.02
P/S (TTM)—
P/B (TTM)-0.29
Revenue (TTM)$0.00
EPS (TTM)$-7.55
Dividend Yield—
ROE (TTM)-1,241.35%
Net Margin0.00%
Gross Margin0.00%
52W High$5.02
52W Low$0.14
Analyst View—
Price Target—
Employees29
Volume957,123

About Lunai Bioworks Inc.

A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.

CEO: David H. Weinstein. Company website

LNAI — Frequently Asked Questions

What is the LNAI stock price today?

Lunai Bioworks Inc. (LNAI) trades at $0.16, down 30.20% on the day, as of Nov 12, 2026 10:46 UTC.

What is Lunai Bioworks Inc.'s market cap?

Lunai Bioworks Inc. has a market capitalisation of $2.93M, calculated from the live LNAI share price and shares outstanding.

What is the P/E ratio of LNAI?

LNAI has no meaningful price-to-earnings ratio: Lunai Bioworks Inc. lost $7.55 per share over the last twelve months, and a P/E is only defined on positive earnings.

How much revenue does Lunai Bioworks Inc. make?

Lunai Bioworks Inc. generated revenue of $0.00 over the trailing twelve months.

What is the 52-week range for LNAI?

LNAI has traded between $0.14 and $5.02 over the past 52 weeks, and the last price is 96.7% below that high.

Is Lunai Bioworks Inc. profitable?

Yes. Lunai Bioworks Inc. keeps 0.00% of revenue as net income over the trailing twelve months.

What sector is Lunai Bioworks Inc. in?

Lunai Bioworks Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .

Who is the CEO of Lunai Bioworks Inc.?

David H. Weinstein is the chief executive of Lunai Bioworks Inc., which employs 29 people.

Where can I track LNAI in real time?

QFI Terminal shows LNAI with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See LNAI live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open LNAI in Terminal See plans

Biotechnology stocks

REGN Regeneron Pharmaceuticals, Inc. VRTX Vertex Pharmaceuticals Incorporated ONC BeOne Medicines AG INCY Incyte Corporation ALNY Alnylam Pharmaceuticals, Inc. JAZZ Jazz Pharmaceuticals plc ARGX argenx SE GMAB Genmab A/S NBIX Neurocrine Biosciences, Inc. BMRN BioMarin Pharmaceutical Inc. UTHR United Therapeutics Corporation CDT CDT Equity Inc. MRNA Moderna, Inc. EXEL Exelixis, Inc. BNTX BioNTech SE SRPT Sarepta Therapeutics, Inc. HALO Halozyme Therapeutics, Inc. INSM Insmed Incorporated MDGL Madrigal Pharmaceuticals, Inc. TECH Bio-Techne Corporation ASND Ascendis Pharma A/S CAI Caris Life Sciences, Inc. IONS Ionis Pharmaceuticals, Inc. BBIO BridgeBio Pharma, Inc.

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. CNC Centene Corp. ELV Elevance Health Inc. HUM Humana Inc. JNJ Johnson & Johnson LLY Eli Lilly and Company HCA HCA Healthcare, Inc. MRK Merck & Co., Inc. ABBV AbbVie Inc. PFE Pfizer Inc.